Ionis Pharmaceuticals Starts Phase 1/2 Clinical Trial of Alzheimer’s Therapy IONIS-MAPTRx

Ionis Pharmaceuticals Starts Phase 1/2 Clinical Trial of Alzheimer’s Therapy IONIS-MAPTRx
Ionis Pharmaceuticals has started a Phase 1/2 clinical trial to evaluate the Alzheimer’s therapy IONIS-MAPTRx. IONIS-MAPTRx is aimed at reducing the production of tau protein, whose accumulation in the brain is a hallmark of the disease. The trial will evaluate the therapy in patients with mild forms of Alzheimer’s. Therapies targeting clusters of a toxic form of tau could

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *